CG Oncology, Inc. announced final results from the Phase 2 CORE-001 clinical trial of its oncolytic immunotherapy candidate, cretostimogene, in combination with pembrolizumab for the treatment of BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) with Carcinoma in Situ (CIS). The data will be presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting from May 31-June 4, in Chicago, IL.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
31.43 USD | -2.12% | -9.32% | 0.00% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 2.09B | |
+34.14% | 51.12B | |
-6.54% | 39.4B | |
+34.92% | 38.48B | |
-12.11% | 26.22B | |
+12.62% | 26.36B | |
-13.43% | 20.96B | |
+43.73% | 14.02B | |
+31.81% | 12.49B | |
-4.54% | 11.61B |
- Stock Market
- Equities
- CGON Stock
- News CG Oncology, Inc.
- CG Oncology, Inc. to Present Positive Final Results from Phase 2 Core-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC At Asco 2024 Annual Meeting